CTR acquires preclinical toxicology company

Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimised toxicological support. From April 1, TKT is a fully owned subsidiary to the holding company CTR.

The activities at TKT will continue without interruption and with the same staff, in the same facilities in Södertälje, Sweden. Elinor Hahne will continue to lead the team as CEO. The company will strengthen their partnership with the other companies in the CTR group, which means shortened communications paths and easier connection between preclinic and clinic.

“We are very proud to welcome the TKT team to CTR. Their expertise in toxicology combined with the CTR group´s expertise in clinical translational research will enable an efficient seamless service to our clients in bringing new products to the market. The ultimate winners are the patients who will get access to new and improved products sooner”, says Bengt Dahlström, chairman of the board at CTR.

Elinor Hahne, CEO at TKT comments: “We are very happy to be part of the CTR group and we are looking forward to adding even more value and expertise to our clients”.

With their seven PhD toxicologists, TKT is one of the largest toxicology consultant companies in the Nordic countries. The company was founded in 2012 and has since then supported a large number of clients to successful regulatory submissions for pharmaceutical and medical device projects. All consultants have extensive experience and expertise in risk assessment of candidate drugs, inactive ingredients, impurities as well as leachables in containers and equipment.

CTR was founded in 2016 and is the holding company for an expanding group of clinical research organisations (CROs) engaged in translational research. CTR owns Clinical Trial Consultants AB, RegSmart Life Science AB, Lablytica Life Science AB and ClinSmart Sweden AB.

Karin Meyer, ny VD för CTR

Karin Meyer blir ny VD för Center for Translational Research Sweden AB (CTR)

CTR tillkännager att styrelsen har utsett Karin Meyer till ny verkställande direktör. Karin Meyer efterträder Mats Lindquist som varit verkställande direktör sedan starten av CTR 2016.

Karin Meyer har en lång erfarenhet av ledande befattningar inom läkemedels- och biotechindustrin, god branschkännedom och en mycket god förståelse för utveckling av nya produkter inom dessa områden. Karin, som är disputerad farmaceut, kommer tillträda jobbet som VD för CTR den 1 maj och kommer då närmast från VD-befattningen på Apotekarsocieteten.

Det är med stor glädje vi lyckats attrahera en så kvalificerad person som Karin Meyer till rollen som verkställande direktör för CTR. Karins långa erfarenhet och goda förståelse för utveckling av nya produkter inom Life Science är en utomordentlig grund för att leda den framtida expansionen av CTR:s verksamheter på den nationella och internationella marknaden, säger Bengt Dahlström, styrelseordförande för CTR.

Jag ser verkligen fram emot uppdraget och att, tillsammans med styrelsen och bolagen i CTR-sfären, fortsätta expandera verksamheten. Att bygga en stark och väl sammanhållen struktur för att tillgängliggöra kompetens för nationella och internationella kunder inom läkemedels- och medicinteknikområdet är viktigt för Life Science i Sverige och även något jag personligen brinner för, säger Karin Meyer.

Mats Lindquist har efter en lång och framgångsrik karriär inom Life Science nu beslutat trappa ned sina engagemang och prioritera rollen som pensionär.

Jag vill tacka Mats Lindquist för hans ovärderliga insatser och aldrig sviktande stöd i vårt gemensamma arbete med CTR:s expansionsstrategi och praktiska arbete med att bygga upp en högspecialiserad forskningsorganisation, säger Bengt Dahlström, styrelseordförande för CTR.

CTR är ett holdingbolag som äger Clinical Trial Consultants, RegSmart Life Science, Lablytica Life Science och ClinSmart Sweden.

Bengt Dahlström
Styrelseordförande
Center for Translational Research Sweden AB

David Pekar, CEO at Lablytica

David Pekar becomes CEO at Lablytica

Lablytica Life Science AB started in November 2019 when Recipharm’s GLP bioanalysis business was divested to Center for Translational Research AB (CTR). David Pekar has since then been the Site Manager and Chief Scientific Officer at Lablytica. As announced by CTR, David will from November 1 2020 be the CEO of Lablytica.

David Pekar announced the news on his LinkedIn page, writing the following:

“I am are excited to announce that I have taken on the role as CEO of Lablytica Life Science. During my time as Chief Scientific Officer I continued to gain experience in all practical matters of organizing, as well as building and expanding the company.

This would not have been possible without the great people working at Lablytica, as well as the fantastic board of CTR. I thank all of you for your ongoing support and hard work in making Lablytica a success.

I cannot wait to see where this new chapter of my career will take me, and to grow and learn within this role”.

Recipharm divests bioanalysis business to Center for Translational Research AB further strengthening existing partnership with CTC Clinical Trial Consultants AB

Recipharm, the contract development and manufacturing organisation, and CTC Clinical Trial Consultants have strengthened their partnership with the divestment of Recipharm’s GLP bioanalysis business to the Center for Translational Research AB (CTR) group. CTR is the Uppsala based parent company of CTC Clinical Trial Consultants.

Recipharm and CTC Clinical Trial Consultants partnered in 2017 to form Recipharm Pathway to Clinic, an integrated service that offers a clear, streamlined pathway to first-in-human milestones. As part of the solution, Recipharm performs formulation development and GMP clinical supply manufacture, whilst CTC Clinical Trial Consultants is responsible for early phase clinical trials (Phase 0–IIa).

The GLP bioanalysis laboratory will now continue its assignments as a newly formed company, Lablytica Life Science AB, 100% owned by CTR.

The analytical activities will continue without interruption with the same staff, in the same facilities, using the same instrumentation and most importantly, the same validated analytical methods. David Pekar, Head of Bioanalysis, will continue to lead the team.

Maria Lundberg, VP Global Analytical Development at Recipharm says: “We are pleased to announce this divestment which allows us to focus on delivering a comprehensive offering from medicinal chemistry through to commercial API manufacturing. This step also further improves the Recipharm Pathway to Clinic offering, where Recipharm continues to facilitate clinical trials by developing and supplying the clinical trial material. The GLP laboratory will now operate within the same group as CTC Clinical Trial Consultants which is a far more logical approach and will result in the even more efficient conduct of clinical trials ultimately improving the result for our customers.”

Bengt Dahlström, Chairman of the Board at CTR comments: “Through the formation of Lablytica as a sister company to CTC Clinical Trial Consultants we believe we will be able to offer a more integrated approach and develop the services for our customers using the talented staff and facilities in the GLP bioanalysis business. The partnership with Recipharm provides a complete solution for first-in-human projects.”